Community Acquired Pneumonia – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Community Acquired Pneumonia – Pipeline Review, H2 2018’, provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia

– The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects

– The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biotest AG

InflaRx NV

ioGenetics Inc

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Nabriva Therapeutics plc

Paratek Pharmaceuticals Inc

ProThera Biologics Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

Tetraphase Pharmaceuticals Inc

TiGenix NV

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Community Acquired Pneumonia - Overview

Community Acquired Pneumonia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Community Acquired Pneumonia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Community Acquired Pneumonia - Companies Involved in Therapeutics Development

Biotest AG

InflaRx NV

ioGenetics Inc

Kyorin Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Nabriva Therapeutics plc

Paratek Pharmaceuticals Inc

ProThera Biologics Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

Tetraphase Pharmaceuticals Inc

TiGenix NV

Wockhardt Ltd

Community Acquired Pneumonia - Drug Profiles

BT-086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAL-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceftaroline fosamil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cx-611 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBAF-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delafloxacin meglumine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nafithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemonoxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PneumoMab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins for Community Acquired Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tebipenem pivoxil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Community Acquired Pneumonia - Dormant Projects

Community Acquired Pneumonia - Discontinued Products

Community Acquired Pneumonia - Product Development Milestones

Featured News & Press Releases

Jun 20, 2018: Paratek Announces FDA Advisory Committee Date for Omadacycline

Jun 07, 2018: Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

May 31, 2018: Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe

May 29, 2018: Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

May 22, 2018: Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

May 21, 2018: Nabriva Therapeutics Announces Positive Top line Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia

Apr 23, 2018: Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID

Apr 13, 2018: Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia

Apr 12, 2018: Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018

Apr 04, 2018: Paratek's New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA

Feb 05, 2018: Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections

Jan 15, 2018: Pfizer’s Zinforo Rejects For Use Within NHS Scotland

Jan 03, 2018: Paratek Provides Update on Omadacycline Tosylate

Dec 20, 2017: Trimodulin: Concept for phase III study successfully coordinated with the authorities

Dec 04, 2017: Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Community Acquired Pneumonia, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Community Acquired Pneumonia – Pipeline by Biotest AG, H2 2018

Community Acquired Pneumonia – Pipeline by InflaRx NV, H2 2018

Community Acquired Pneumonia – Pipeline by ioGenetics Inc, H2 2018

Community Acquired Pneumonia – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Community Acquired Pneumonia – Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Community Acquired Pneumonia – Pipeline by Melinta Therapeutics Inc, H2 2018

Community Acquired Pneumonia – Pipeline by Merck & Co Inc, H2 2018

Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics plc, H2 2018

Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc, H2 2018

Community Acquired Pneumonia – Pipeline by ProThera Biologics Inc, H2 2018

Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd, H2 2018

Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Community Acquired Pneumonia – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018

Community Acquired Pneumonia – Pipeline by TiGenix NV, H2 2018

Community Acquired Pneumonia – Pipeline by Wockhardt Ltd, H2 2018

Community Acquired Pneumonia – Dormant Projects, H2 2018

Community Acquired Pneumonia – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Community Acquired Pneumonia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports